Inverse variance weighted (IVW) estimation indicated that genetically proxied SGLT2 inhibition was significantly associated with a reduced risk of liver fibrosis/cirrhosis (Figure 1A). This evidence concerns the gene SLC5A2 and Hepatic fibrosis.